Navigation Links
Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
Date:9/25/2007

SAN DIEGO, Sept. 25 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that enrollment is complete in its Chemophase(R) Phase I/IIa clinical trial for the treatment of superficial bladder cancer. The Company began dosing patients in this trial in April of last year, following the successful completion of the initial Phase I trial of a single-administration of Chemophase and mitomycin. Patient enrollment in this Phase I/IIa trial required stepwise enrollment by escalating dose cohort, with a pause for safety evaluation required after the last patient in the previous cohort had completed at least the first four of the six weekly study drug instillations. Chemophase is a novel recombinant investigational therapeutic being developed to enhance the delivery of chemotherapy.

The Chemophase Phase I/IIa clinical trial is a multi-center, open label, nonrandomized study to evaluate multiple intravesical (into the bladder) administrations of Chemophase along with the widely used anticancer drug mitomycin in patients with superficial bladder cancer. This dose-finding Phase I/IIa study enrolled 27 patients with superficial bladder cancer. The objectives of the study included determining the maximum tolerated dose (MTD) and dose-limiting toxicities, if any, of escalating doses of mitomycin and then Chemophase in combination with mitomycin administered as weekly intravesical instillations for six weeks, consistent with the usual standard of care; establishing the optimal dose of Chemophase with mitomycin to be recommended for future studies; and observing patients for any preliminary evidenc
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... TUCSON, Ariz. , May 23, 2013 ... world,s first and only FDA, Health Canada and CE ... announced today that the Glasgow Science Centre in ... visitors annually, is featuring the SynCardia temporary Total ... as part of its $3 million Bodyworks Exhibition, one ...
(Date:5/23/2013)... -- InspireMD, Inc. ("InspireMD" or the ... protection stents, today announced new 6-month results from ... trial demonstrating that the MGuard Embolic Protection Stent ... in all-cause mortality in ST segment elevation myocardial ... presented at the InspireMD STEMI Symposium at EuroPCR, ...
(Date:5/23/2013)...  PAREXEL International Corporation (NASDAQ: PRXL ) ... Jefferies Healthcare Conference in New York.  James ... Officer, will be making a presentation on PAREXEL and ... 3, 2013. A live webcast of the ... PAREXEL,s website at www.PAREXEL.com in the Upcoming ...
Breaking Medicine Technology:Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5PAREXEL International To Present At Jefferies Healthcare Conference 2
... Mich., Feb. 16, 2012  Waltonen Engineering, Inc., a ... announce that it has been awarded a U.S. ... Services (PES) Contract. "Waltonen currently ... Tank Automotive Research Development Engineering Center (TARDEC), Tank ...
... likelihood that Medicare beneficiaries are not receiving necessary medical ... urging Congress to adopt the Market Pricing Program ... home medical equipment and services, or durable medical equipment ... and Medicaid Services (CMS), which implemented the bidding program ...
Cached Medicine Technology:American Association for Homecare Calls for Market-Based Alternative to Medicare's Bidding Program; Cites Lack of Access for Beneficiaries 2American Association for Homecare Calls for Market-Based Alternative to Medicare's Bidding Program; Cites Lack of Access for Beneficiaries 3American Association for Homecare Calls for Market-Based Alternative to Medicare's Bidding Program; Cites Lack of Access for Beneficiaries 4
(Date:5/23/2013)... journal Science published an article about bexarotene ... an important starting point for further Alzheimer,s research. The ... at VIB and KU Leuven in collaboration with ... and scientists at Janssen Pharmaceutica, Beerse, also tested this ... results were different, as were those of two American ...
(Date:5/23/2013)... - Even while being dragged to its destruction ... fires away, sending signals that thwart the development ... reported in an early online publication at ... often encountered by tumors, the epidermal growth factor ... an international team led by scientists at The ...
(Date:5/23/2013)... 23, 2013 The Rottenstein Law Group ... has created the Tylenol Lawsuit Information Center at ... users and those who are considering filing lawsuits. ... potentially cause severe liver damage, according to a 2009 ... In the “safety communication,” the FDA warned consumers against ...
(Date:5/23/2013)... The vast majority of Americans believe ... over their level of physical activity, the healthfulness of ... actually taking that control. Those are among the ... 2013 Food & Health Survey. , According to the ... have “a great deal of control” or “complete control” ...
(Date:5/23/2013)... 2013 Jeanne Ettelson, president of ... popular and only free OCD support group in Chicago. ... for OCD sufferers, the group is lead by psychologists ... This allows group participants to learn accurate information ... Prevention. , “Participants in Beyond OCD’s support group ...
Breaking Medicine News(10 mins):Health News:New insights contradict promising Alzheimer's research 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2
... 12 (HealthDay News) -- The U.S. Department of Health and ... $185 million to 13 states and the District of Columbia ... cornerstone of President Obama,s health care reform -- across the ... the plan, which will include tax relief to give families ...
... (HealthDay News) -- Dogs can teach children about responsibility, ... maintain their reading skills. Researchers found that reading ... some second-graders, ability to read and their attitude about ... adults experienced declines in both areas, the study found. ...
... -- Although being physically active is one of the best ... ability to get around, a new study shows that people ... thought. Researchers from Northwestern University Feinberg School of Medicine ... of men with knee osteoarthritis are basically "couch potatoes," and ...
... Aug. 12 (HealthDay News) -- Monthly premiums for individual health ... vary widely from state to state, a new report says. ... $136 a month in Alabama to more than $400 a ... the non-profit Kaiser Family Foundation. The foundation said the ...
... published in the American Journal of Industrial Medicine ... of the New York City Fire Department (FDNY) resulting ... David J. Prezant, MD, Chief Medical Officer, FDNY, researchers ... 11, 1994, and September 10, 2008, comparing the total ...
... Hawn Foundation, will present a lecture for the public ... jointly sponsored by the New York Academy of Sciences ... about the MindUP curriculum, the Foundation,s signature educational initiative ... emotional learning program designed for pre-kindergarten through eighth-grade children, ...
Cached Medicine News:Health News:Feds Outline Rules for States' Insurance Exchanges 2Health News:Fido's New Forte: Helping Kids Learn to Read 2Health News:Many Arthritis Patients May Not Be Exercising Enough 2
... determination of Estradiol (E2) concentration in human serum ... hormone with a phenolic A ring. This ... It is the most potent natural Estrogen, ... smaller amounts by the adrenal cortex, and the ...
... The DSL-10-39100 3rd Generation Estradiol ... estradiol in serum. Estradiol measurements ... and treatment of various hormonal ... placental function in complicated pregnancy. ...
... has been useful in the differential diagnosis ... with chest pain. 18-20 ... of sensitive and specific biomarkers, such as ... kinase (CK-MB), and myoglobin, are increased in ...
... is the most potent, naturally secreted estrogen ... the ovary [1]. In the ovary, estradiol ... estrone, a less potent estrogen derived from ... many body tissues. In men, small amounts ...
Medicine Products: